ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

neridronic acid

Also written as “Neridronate”, “Neridronic acid 100 mg” and “Neridronic acid”.

Its studies are mostly in Complex Regional Pain Syndromes · Reflex Sympathetic Dystrophy, led by 2 companies.

Drug pageNeridronic acid: every studyAll 8 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Mar 25, 20156 company-led studies, 2 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Grünenthalits history only40 open or runningphase 3since Mar 25, 2015Mar 25, 2015none ahead
Ambros Therapeutics22 open or runningphase 3since Sep 17, 2025Sep 17, 2025Dec 2027phase 3 · NCT07210515

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Ambros Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 17, 2025First study: phase 3 study in Complex Regional Pain SyndromesFirst studyNCT07210515 · 270 planned · United States
  2. Sep 24, 2026Phase 3 study in Complex Regional Pain SyndromesNCT07857733 · 135 planned · United States

Ahead

  1. Dec 2027Primary completion: phase 3 study in Complex Regional Pain SyndromesNCT07210515
  2. Dec 31, 2028Primary completion: phase 3 study in Complex Regional Pain SyndromesNCT07857733

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 2 Ambros Therapeutics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07857733Complex Regional Pain Syndromes · United States3RecruitingDec 31, 2028135
NCT07210515Complex Regional Pain Syndromes · United States3RecruitingDec 2027270

How it is read

Names in the registry

  • “Neridronate”, 2 entries
  • “Neridronic acid 100 mg”, 2 entries
  • “Neridronic acid”, 1 entry
  • “Neridronic acid 62.5 mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.